# Sanofi to acquire vaccine maker Dynavax Technologies in $2.2 billion deal

**Category:** Business
**Source:** [https://cen.acs.org/business/mergers-&-acquisitions/sanofi-buys-dynavax-technologies/104/web/2026/01](https://cen.acs.org/business/mergers-&-acquisitions/sanofi-buys-dynavax-technologies/104/web/2026/01)
**Publisher:** Chemical & Engineering News (C&EN)
**Published:** 2026-01-06
**Scraped (UTC):** 2026-01-08T03:55:14+00:00

## Summary
Sanofi has agreed to buy U.S.-based Dynavax Technologies, a specialist in vaccines for hepatitis B and shingles, valuing the company at about $2.2 billion. Dynavax’s flagship hepatitis B vaccine Heplisav‑B, approved for U.S. adults in late 2024, will strengthen Sanofi’s vaccine portfolio and market position.

## Full Article
*(Article text could not be extracted. Visit source link above.)*

---

*Content scraped from public sources with attribution. Users assume all risk.*  
*Auto-generated by [Perplexity News Tracker](https://github.com/myidkd1-coder/perplexity-news-tracker)*